Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Patients who received Opdivo plus Yervoy maintained durable responses, with the combination showing improved duration of response vs. sunitinib